Сравнение
DSIP vs. Linaclotid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
62568-57-4
851199-59-2
Молекулярная масса
848.81 g/mol
1526.74 g/mol
Период полувыведения
0.1 h
нет данных
Последовательность
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Gluнет данных
Механизм действия
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
4
0
из них на людях
1
0
Зафиксированные эффекты
3
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between DSIP and Linaclotid?
- DSIP is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Linaclotid?
- The highest available evidence level is "Исследование на людях" for DSIP and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Linaclotid in Germany and the United States?
- Германия: DSIP — Не одобрено, Linaclotid — Рецептурный. США: DSIP — Не одобрено, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.